Recurrent Melanoma Completed Phase 1 / 2 Trials for Bevacizumab (DB00112)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00074308Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced CancersTreatment